This preclinical-stage biotech company develops non-hormonal therapeutics for women's reproductive health. Their pipeline includes programs addressing ovarian senescence, contraception, endometriosis, and polycystic ovary syndrome.
Funding
$3.5M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Current hormonal treatments for women's reproductive health conditions, such as endometriosis, PCOS, and infertility, often have unfavorable side effects and high recurrence rates. Many women's health conditions are rooted in ovarian dysfunction and are still being treated with hormonal interventions introduced over 50 years ago. There is a need for non-hormonal, disease-modifying therapeutics that address the underlying causes of these conditions.
Solution
Celmatix Therapeutics is a preclinical-stage biotech company pioneering ovarian health therapeutics by developing novel, non-hormonal interventions for women's reproductive health conditions. The company's pipeline includes drug programs targeting ovarian aging, infertility, endometriosis, and polycystic ovary syndrome (PCOS). Celmatix utilizes a proprietary multi-omic ovarian health platform to identify novel drug targets and develop first-in-class therapies. Their approach centers on new biology and novel approaches to solve long-standing problems, addressing areas of high unmet need and paving the way for the future of women’s health.
Target Audience
The primary target audience includes women affected by reproductive health conditions such as endometriosis, premature menopause, polycystic ovary syndrome (PCOS), and infertility, as well as healthcare providers specializing in women's health.
Features
- AMHR2 agonist program focused on ovarian aging to align ovarian function with the modern lifespan
- Oral FSH receptor agonist for infertility to transform the fertility treatment paradigm
- JNK inhibitor for endometriosis to minimize inflammation and allow disease remission through non-hormonal therapy
- Novel Jun-N-terminal kinase (JNK) inhibitor that targets pain and inflammation
- Oral bioavailability and biological activity in rodent model for injectable FSH drugs
- Targets the FSH receptor without affecting the closely related thyroid hormone receptor (TSHR)
- Proprietary multi-omic ovarian health platform, the world’s largest of its kind